Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations.
Cytomegalovirus (CMV) continues to cause significant morbidity and mortality in lung transplant recipients. This article presents recommendations based on available evidence for the optimal management of CMV in lung transplant recipients, which have been developed by an expert committee of transplant physicians-surgeons and infectious disease specialists.
Zamora
Martin R
MR
Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver, CO 80262, USA. marty.zamora@uchsc.edu
Davis
R Duane
RD
Leonard
Colm
C
D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D003586:Cytomegalovirus Infections / Q000517:prevention & control*; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine / Q000592:standards*; D015774:Ganciclovir / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D016040:Lung Transplantation / Q000009:adverse effects*; D011183:Postoperative Complications / Q000517:prevention & control / Q000821:virology*; D011785:Quality Assurance, Health Care; D000077562:Valganciclovir
D000998:Antiviral Agents; D000077562:Valganciclovir; D015774:Ganciclovir